On November 9, Surgery Partners, an operator of surgical centers across the United States, told shareholders that its board had turned down an unsolicited proposal of $28.00 per share in cash and instead raised the price in its existing merger agreement to $25.00 per share. The special committee that reviewed the proposal concluded that it was not a "superior proposal" as the merger agreement defines the term, mainly because the signed deal was more likely to close, and to close sooner. For owners who may someday receive more than one offer, the case shows why the highest number on the table is only one input in comparing bids.
Surgery Partners announced on October 26 that it had agreed to be acquired by HealthSpan Partners, an affiliate of the Bon Secours Mercy Health system, for $23.50 per share in cash. The transaction was valued at about $5.7 billion including debt, a figure known as enterprise value, which adds a company's net debt to the price paid for its shares. On November 3, according to the company, an unnamed third party submitted a non-binding proposal at $28.00 per share and updated it on November 8. Bloomberg reported, citing a person familiar with the matter, that the bidder was UnitedHealth Group. UnitedHealth declined to comment, and Surgery Partners' own release refers only to a third party.
The next day, Surgery Partners and HealthSpan announced an amended agreement. HealthSpan raised its cash price to $25.00 per share, about 6.4% above the original, and added a ticking fee, described below. At its maximum the deal is valued at up to about $6.0 billion in enterprise value. The company still expects to close in the first quarter of 2027, subject to a stockholder vote, regulatory approvals, and customary conditions.
Surgery Partners' special committee, made up entirely of independent and disinterested directors, unanimously found that the $28.00 proposal was not a "Superior Proposal" under the HealthSpan agreement. Merger agreements typically let a board engage with a rival bid only if it meets a defined standard, and that standard usually weighs price alongside the likelihood and timing of closing. The company gave three reasons: the third-party deal would likely take materially longer to close, or might not close; it carried greater regulatory risk and complexity; and it lacked contractual protections the committee wanted.
It helps to compare what each side was actually offering. The $28.00 proposal was non-binding, which means the bidder had committed to nothing and no agreement had been negotiated. HealthSpan holds a signed agreement and says it has secured commitments for the new debt it will use, along with cash on hand, to pay for the deal. A non-binding offer and a signed contract with committed financing are different instruments, even when the first carries the bigger number.
The ticking fee is a direct payment for time. If stockholders approve the merger but it has not closed by March 1, 2027, shareholders other than Bain Capital receive additional cash, paid monthly in arrears, at a rate of 10% per year on the $25.00 price. The fee reaches a maximum of $1.61 per share if closing slips to the October 23, 2027 outside date, which is the deadline after which either side may end the agreement. At that point the total would be $26.61 per share.
Sellers can use this idea whenever a deal faces a long approval process. If regulatory review runs past the expected date, the seller is compensated for waiting, and the buyer has a financial reason to move quickly. The numbers also show how the board weighed the choice: even at its maximum of $26.61, the signed deal remains about 5% below the $28.00 proposal, and the committee still preferred it.
There is a simple way to frame this kind of decision. Treat $25.00 as the amount if the signed deal closes and $28.00 as the amount if the rival bid closes. The rival price is about 12% higher, so, setting aside timing and what happens if a deal fails, it is worth more in expectation only if its chance of closing is at least about 89% of the signed deal's chance (25 divided by 28). If you believe the signed deal is close to certain, a competing bid has to be close to certain as well before the higher price pays off.
This is an illustration, not a valuation of either offer, and it leaves out costs that matter in practice. A failed sale does not return a company to where it started. Employees, customers, and competitors know the business was for sale, management attention has been spent, and the next buyer may offer less. Those costs make certainty worth more than a pure price comparison suggests.

Bain Capital affiliates own about 39% of Surgery Partners. Under the amended terms they receive no cash, including no ticking fee, and instead roll their shares into equity of the acquiring entity, remaining a significant partner after closing. They had already signed a voting and support agreement to vote for the merger, and that agreement remains in place. The company has not described Bain's reasoning, so we draw no conclusion about it.
The structure does illustrate a general point. A rollover, in which a seller reinvests part of its proceeds in the buyer's equity, changes the seller's incentives. An owner who keeps a stake cares about the buyer's financing and long-term plan as well as the cash price. Shareholders paid fully in cash care mainly about price and timing, which is the reason a committee of independent directors reviews bids in a situation like this one.
Several things will show how this plays out. One is whether the third party returns with a binding proposal that addresses the committee's concerns about timing, regulatory risk, and contractual protections. Another is the stockholder vote, which the board has recommended. A third is the regulatory review that both the amended deal and any rival deal would need to pass. The release does not disclose termination fees, so the cost of walking away from the signed agreement is not yet public.
For owners of private companies, the larger lesson does not depend on this outcome. When offers differ, ask what each one is worth after weighing the chance it closes, the time it takes, and the protections you receive if it does not.
Surgery Partners' board chose a signed $25.00 per share deal, with a ticking fee that can lift it to $26.61, over a non-binding $28.00 proposal that it judged slower, riskier, and less protected. Owners comparing offers should look past the headline price to whether each bid is binding and financed, how long approvals will take, what compensation exists for delay, and what a failed deal would cost the business.